Avandia (rosiglitazone) increases the risk of heart attack
June 2007
Patients are asking about the news that Avandia (rosiglitazone) increases the risk of heart attack.
A new meta-analysis suggests a higher risk of heart attacks in patients taking rosiglitazone compared to other meds or placebo.
Experts crunching the same numbers come up with differing conclusions, and point out the study's shortcomings. The complicated statistics are explored in our Detail-Document.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote